Individual Variation in Lipidomic Profiles of Healthy Subjects in Response to Omega-3 Fatty Acids

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Nording, Malin L ^a,b   Yang, Jun ^b   Georgi, Katrin ^b   Hegedus Karbowski, Christine ^b   German, J Bruce ^b   Weiss, Robert H ^b,c   Hogg, Ronald J ^d   Trygg, Johan ^a   Hammock, Bruce D ^b   Zivkovic, Angela M ^b  

^a UMEÅ UNIVERSITY   (Sweden)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

12 HYDROXYICOSATETRAENOIC ACID; ARACHIDONIC ACID; CHOLESTEROL ESTER; DIACYLGLYCEROL; DOCOSAHEXAENOIC ACID; FATTY ACID; ICOSAPENTAENOIC ACID; LIPID; LIPOPROTEIN; LIPOXYGENASE; LYSOPHOSPHATIDYLCHOLINE; OMEGA 3 FATTY ACID; OXYLIPIN; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; THROMBOXANE B2; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL TRIAL; CORRELATION ANALYSIS; DIET SUPPLEMENTATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPIDOMICS; MALE; NORMAL HUMAN; OPEN STUDY; PHENOTYPE; PILOT STUDY; RISK MANAGEMENT; VOLUNTEER;

ADULT; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; LIPID METABOLISM; LIPIDS; LIPOPROTEINS; MALE; METABOLOMICS; MIDDLE AGED; OXYLIPINS; PILOT PROJECTS; RISK FACTORS; YOUNG ADULT;

EID: 84886239681     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076575     Document Type: Article

References (57)

1. Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS, (2012) Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA 308: 1024-1033. doi:10.1001/2012.jama.11374. PubMed: 22968891.
2. Bang HO, Dyerberg J, Nielsen AB, (1971) Plasma lipid and lipoprotein pattern in Greenlandic West-coast Eskimos. Lancet 1: 1143-1145. PubMed: 4102857.
3. Burr ML, Ashfield-Watt PA, Dunstan FD, Fehily AM, Breay P, et al. (2003) Lack of benefit of dietary advice to men with angina: results of a controlled trial. Eur J Clin Nutr 57: 193-200. doi:10.1038/sj.ejcn.1601539. PubMed: 12571649.
4. Burr ML, (2007) Secondary prevention of CHD in UK men: the Diet and Reinfarction Trial and its sequel. Proc Nutr Soc 66: 9-15. doi:10.1017/S0029665107005241. PubMed: 17343767.
5. de Roos B, Mavrommatis Y, Brouwer IA, (2009) Long-chain n-3 polyunsaturated fatty acids: new insights into mechanisms relating to inflammation and coronary heart disease. Br J Pharmacol 158: 413-428. doi:10.1111/j.1476-5381.2009.00189.x. PubMed: 19422375.
6. Harris WS, Mozaffarian D, Lefevre M, Toner CD, Colombo J, et al. (2009) Towards establishing dietary reference intakes for eicosapentaenoic and docosahexaenoic acids. J Nutr 139: 804S-819S. doi:10.3945/jn.108.101329. PubMed: 19244379.
7. Lopez-Huertas E, (2012) The effect of EPA and DHA on metabolic syndrome patients: a systematic review of randomised controlled trials. Br J Nutr 107 (Suppl 2):: S185-S194. doi:10.1017/S0007114512001572. PubMed: 22591892.
8. Cottin SC, Sanders TA, Hall WL, (2011) The differential effects of EPA and DHA on cardiovascular risk factors. Proc Nutr Soc 70: 215-231. doi:10.1017/S0029665111000061. PubMed: 21349231.
9. Hartweg J, Farmer AJ, Perera R, Holman RR, Neil HA, (2007) Meta-analysis of the effects of n-3 polyunsaturated fatty acids on lipoproteins and other emerging lipid cardiovascular risk markers in patients with type 2 diabetes. Diabetologia 50: 1593-1602. doi:10.1007/s00125-007-0695-z. PubMed: 17541540.
10. Mozaffarian D, Wu JH, (2012) (n-3) fatty acids and cardiovascular health: are effects of EPA and DHA shared or complementary? J Nutr 142: 614S-625S. doi:10.3945/jn.111.149633. PubMed: 22279134.
11. Bernstein AM, Ding EL, Willett WC, Rimm EB, (2012) A meta-analysis shows that docosahexaenoic acid from algal oil reduces serum triglycerides and increases HDL-cholesterol and LDL-cholesterol in persons without coronary heart disease. J Nutr 142: 99-104. doi:10.3945/jn.111.148973. PubMed: 22113870.
12. Kelley DS, Adkins Y, Woodhouse LR, Swislocki A, Mackey BE, et al. (2012) Docosahexaenoic acid supplementation improved lipocentric but not glucocentric markers of insulin sensitivity in hypertriglyceridemic men. Metab Syndr Relat Disord 10: 32-38. doi:10.1089/met.2011.0081. PubMed: 21999398.
13. Armstrong P, Kelley DS, Newman JW, Staggers FE Sr., Hartiala J, et al. (2012) Arachidonate 5-lipoxygenase gene variants affect response to fish oil supplementation by healthy African Americans. J Nutr 142: 1417-1428. doi:10.3945/jn.112.159814. PubMed: 22739369.
14. Kelley DS, Taylor PC, Nelson GJ, Schmidt PC, Ferretti A, et al. (1999) Docosahexaenoic acid ingestion inhibits natural killer cell activity and production of inflammatory mediators in young healthy men. Lipids 34: 317-324. doi:10.1007/BF02562331. PubMed: 10443964.
15. Lee TH, Hoover RL, Williams JD, Sperling RI, Ravalese J 3rd, et al. (1985) Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function. N Engl J Med 312: 1217-1224. doi:10.1056/NEJM198505093121903. PubMed: 2985986.
16. Lee TH, Mencia-Huerta JM, Shih C, Corey EJ, Lewis RA, et al. (1984) Effects of exogenous arachidonic, eicosapentaenoic, and docosahexaenoic acids on the generation of 5-lipoxygenase pathway products by ionophore-activated human neutrophils. J Clin Invest 74: 1922-1933. doi:10.1172/JCI111612. PubMed: 6096400.
17. Lee TH, Menica-Huerta JM, Shih C, Corey EJ, Lewis RA, et al. (1984) Characterization and biologic properties of 5,12-dihydroxy derivatives of eicosapentaenoic acid, including leukotriene B5 and the double lipoxygenase product. J Biol Chem 259: 2383-2389. PubMed: 6321468.
18. von Schacky C, Kiefl R, Marcus AJ, Broekman MJ, Kaminski WE, (1993) Dietary n-3 fatty acids accelerate catabolism of leukotriene B4 in human granulocytes. Biochim Biophys Acta 1166: 20-24. doi:10.1016/0005-2760(93)90278-H. PubMed: 8381674.
19. Ottestad I, Hassani S, Borge GI, Kohler A, Vogt G, et al. (2012) Fish oil supplementation alters the plasma lipidomic profile and increases long-chain PUFAs of phospholipids and triglycerides in healthy subjects. PLOS ONE 7: e42550. doi:10.1371/journal.pone.0042550. PubMed: 22952598.
20. Shearer GC, Harris WS, Pedersen TL, Newman JW, (2010) Detection of omega-3 oxylipins in human plasma and response to treatment with omega-3 acid ethyl esters. J Lipid Res 51: 2074-2081. doi:10.1194/M900193-JLR200. PubMed: 19671931.
21. Zivkovic AM, Yang J, Georgi K, Hegedus C, Nording ML, et al. (2012) Serum oxylipin profiles in IgA nephropathy patients reflect kidney functional alternations. Metabolomics 8: 1102-1113. doi:10.1007/s11306-012-0417-5. PubMed: 23833568.
22. Lundström SL, Yang J, Brannan JD, Haeggström JZ, Hammock BD, et al. (2013) Lipid mediator serum profiles in asthmatics significantly shift following dietary supplementation with omega-3 fatty acids. Mol Nutr Food Res 57: 1378-1389. doi:10.1002/mnfr.201200827. PubMed: 23824870.
23. Pei J, Zhao Y, Huang L, Zhang X, Wu Y, (2012) The effect of n-3 polyunsaturated fatty acids on plasma lipids and lipoproteins in patients with chronic renal failure--a meta-analysis of randomized controlled trials. J Ren Nutr 22: 525-532. doi:10.1053/j.jrn.2012.04.005. PubMed: 22698988.
24. Kelley DS, Adkins Y, (2012) Similarities and differences between the effects of EPA and DHA on markers of atherosclerosis in human subjects. Proc Nutr Soc 71: 322-331. doi:10.1017/S0029665112000080. PubMed: 22369859.
25. Burillo E, Martín-Fuentes P, Mateo-Gallego R, Baila-Rueda L, Cenarro A, et al. (2012) Omega-3 fatty acids and HDL. How do they work in the prevention of cardiovascular disease? Curr Vasc Pharmacol 10: 432-441. doi:10.2174/157016112800812845. PubMed: 22339302.
26. Jacobson TA, Glickstein SB, Rowe JD, Soni PN, (2012) Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review. J Clin Lipidol 6: 5-18. doi:10.1016/j.jacl.2011.10.018. PubMed: 22264569.
27. Watkins SM, Reifsnyder PR, Pan HJ, German JB, Leiter EH, (2002) Lipid metabolome-wide effects of the PPARgamma agonist rosiglitazone. J Lipid Res 43: 1809-1817. doi:10.1194/jlr.M200169-JLR200. PubMed: 12401879.
28. Zivkovic AM, Wiest MM, Nguyen UT, Davis R, Watkins SM, et al. (2009) Effects of sample handling and storage on quantitative lipid analysis in human serum. Metabolomics 5: 507-516. doi:10.1007/s11306-009-0174-2. PubMed: 20046864.
29. Folch J, Lees M, Sloane Stanley GH, (1957) A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226: 497-509. PubMed: 13428781.
30. Yang J, Schmelzer K, Georgi K, Hammock BD, (2009) Quantitative profiling method for oxylipin metabolome by liquid chromatography electrospray ionization tandem mass spectrometry. Anal Chem 81: 8085-8093. doi:10.1021/ac901282n. PubMed: 19715299.
31. Jeyarajah EJ, Cromwell WC, Otvos JD, (2006) Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med 26: 847-870. doi:10.1016/j.cll.2006.07.006. PubMed: 17110242.
32. Wold S, Esbensen K, Geladi P, (1987) Principal Component Analysis. Chemom Intell Lab Syst 2: 37-52. doi:10.1016/0169-7439(87)80084-9.
33. Bylesjo M, Rantalainen M, Cloarec O, Nicholson J, Holmes E, et al. (2006) OPLS discriminant analysis: combining the strengths of PLS-DA and SIMCA classification. J Chemom 20: 341-351. doi:10.1002/cem.1006.
34. Trygg J, (2002) O2-PLS for qualitative and quantitative analysis in multivariate calibration. J Chemom 16: 283-293. doi:10.1002/cem.724.
35. Eriksson L, Trygg J, Wold S, (2008) CV-ANOVA for significance testing of PLS and OPLS ® models. J Chemom 22: 594-600. doi:10.1002/cem.1187.
36. Harris WS, (1997) n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 65: 1645S-1654S. PubMed: 9129504.
37. Thifault E, Cormier H, Bouchard-Mercier A, Rudkowska I, Paradis AM, et al. (2013) Effects of Age, Sex, Body Mass Index and APOE Genotype on Cardiovascular Biomarker Response to an n-3 Polyunsaturated Fatty Acid Supplementation. J Nutrigenet Nutrigenomics 6: 73-82. doi:10.1159/000350744. PubMed: 23689286.
38. Johnson JL, Slentz CA, Duscha BD, Samsa GP, McCartney JS, et al. (2004) Gender and racial differences in lipoprotein subclass distributions: the STRRIDE study. Atherosclerosis 176: 371-377. doi:10.1016/j.atherosclerosis.2004.05.018. PubMed: 15380461.
39. Minihane AM, Khan S, Leigh-Firbank EC, Talmud P, Wright JW, et al. (2000) ApoE polymorphism and fish oil supplementation in subjects with an atherogenic lipoprotein phenotype. Arterioscler Thromb Vasc Biol 20: 1990-1997. doi:10.1161/01.ATV.20.8.1990. PubMed: 10938022.
40. Mueller BA, Talbert BL, Tegeler CH, (1989) Comparative effects of omega-3 fatty acids in men and women. Clin Pharmacol 8: 328-329. PubMed: 2545407.
41. Gillingham LG, Harding SV, Rideout TC, Yurkova N, Cunnane SC, et al. (2013) Dietary oils and FADS1-FADS2 genetic variants modulate [13C]alpha-linolenic acid metabolism and plasma fatty acid composition. Am J Clin Nutr 97: 195-207. doi:10.3945/ajcn.112.043117. PubMed: 23221573.
42. Keenan AH, Pedersen TL, Fillaus K, Larson MK, Shearer GC, et al. (2012) Basal omega-3 fatty acid status affects fatty acid and oxylipin responses to high-dose n3-HUFA in healthy volunteers. J Lipid Res 53: 1662-1669. doi:10.1194/jlr.P025577. PubMed: 22628615.
43. Harsløf LB, Larsen LH, Ritz C, Hellgren LI, Michaelsen KF, et al. (2013) FADS genotype and diet are important determinants of DHA status: a cross-sectional study in Danish infants. Am J Clin Nutr 97: 1403-1410. doi:10.3945/ajcn.113.058685. PubMed: 23636240.
44. Koletzko B, Lattka E, Zeilinger S, Illig T, Steer C, (2011) Genetic variants of the fatty acid desaturase gene cluster predict amounts of red blood cell docosahexaenoic and other polyunsaturated fatty acids in pregnant women: findings from the Avon Longitudinal Study of Parents and Children. Am J Clin Nutr 93: 211-219. doi:10.3945/ajcn.110.006189. PubMed: 21106917.
45. Lattka E, Illig T, Heinrich J, Koletzko B, (2010) Do FADS genotypes enhance our knowledge about fatty acid related phenotypes? Clin Nutr 29: 277-287. doi:10.1016/j.clnu.2009.11.005. PubMed: 19948371.
46. Moltó-Puigmartí C, Plat J, Mensink RP, Müller A, Jansen E, et al. (2010) FADS1 FADS2 gene variants modify the association between fish intake and the docosahexaenoic acid proportions in human milk. Am J Clin Nutr 91: 1368-1376. doi:10.3945/ajcn.2009.28789. PubMed: 20335541.
47. Xie L, Innis SM, (2008) Genetic variants of the FADS1 FADS2 gene cluster are associated with altered (n-6) and (n-3) essential fatty acids in plasma and erythrocyte phospholipids in women during pregnancy and in breast milk during lactation. J Nutr 138: 2222-2228. doi:10.3945/jn.108.096156. PubMed: 18936223.
48. Bryan DL, Forsyth KD, Hart PH, Gibson RA, (2006) Polyunsaturated fatty acids regulate cytokine and prostaglandin E2 production by respiratory cells in response to mast cell mediators. Lipids 41: 1101-1107. doi:10.1007/s11745-006-5059-9. PubMed: 17269555.
49. Cansell MS, Moussaoui N, Mancini M, (2007) Prostaglandin E2 and interleukin-8 production in human epidermal keratinocytes exposed to marine lipid-based liposomes. Int J Pharm 343: 277-280. doi:10.1016/j.ijpharm.2007.04.014. PubMed: 17532154.
50. LeBlanc CJ, Horohov DW, Bauer JE, Hosgood G, Mauldin GE, (2008) Effects of dietary supplementation with fish oil on in vivo production of inflammatory mediators in clinically normal dogs. Am J Vet Res 69: 486-493. doi:10.2460/ajvr.69.4.486. PubMed: 18380580.
51. Langerhuus SN, Tønnesen EK, Jensen KH, Damgaard BM, Halekoh U, et al. (2012) Effects of dietary n-3 and n-6 fatty acids on clinical outcome in a porcine model on post-operative infection. Br J Nutr 107: 735-743. doi:10.1017/S0007114511003503. PubMed: 21810284.
52. Zulyniak MA, Perreault M, Gerling C, Spriet LL, Mutch DM, (2013) Fish oil supplementation alters circulating eicosanoid concentrations in young healthy men. Metabolism 62: 1107-1113. doi:10.1016/j.metabol.2013.02.004. PubMed: 23522836.
53. Psychogios N, Hau DD, Peng J, Guo AC, Mandal R, et al. (2011) The human serum metabolome. PLOS ONE 6: e16957. doi:10.1371/journal.pone.0016957. PubMed: 21359215.
54. Krokan HE, Bjerve KS, Mørk E, (1993) The enteral bioavailability of eicosapentaenoic acid and docosahexaenoic acid is as good from ethyl esters as from glyceryl esters in spite of lower hydrolytic rates by pancreatic lipase in vitro. Biochim Biophys Acta 1168: 59-67. doi:10.1016/0005-2760(93)90266-C. PubMed: 8504143.
55. Blonk MC, Bilo HJ, Nauta JJ, Popp-Snijders C, Mulder C, et al. (1990) Dose-response effects of fish-oil supplementation in healthy volunteers. Am J Clin Nutr 52: 120-127. PubMed: 2141757.
56. Simopoulos AP, (2008) The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Exp Biol Med (Maywood) 233: 674-688. doi:10.3181/0711-MR-311. PubMed: 18408140.
57. Baum SJ, Kris-Etherton PM, Willett WC, Lichtenstein AH, Rudel LL, et al. (2012) Fatty acids in cardiovascular health and disease: a comprehensive update. J Clin Lipidol 6: 216-234. doi:10.1016/j.jacl.2012.04.077. PubMed: 22658146.